CIK: 0001704132 · Show all filings
Period: Q3 2021 (← Previous) (Next →)
Filing Date: Nov 12, 2021
Total Value ($000): $679,115 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | Kinnate Biopharma Inc. | 9,671,643 | $222,641 | 32.8% | $39.78 | — | COM | 49705R105 |
| — | Lyell Immunopharma, Inc. | 13,282,181 | $196,576 | 28.9% | $16.24 | — | COM | 55083R104 |
| ACRS | Aclaris Therapeutics, Inc. | 3,399,034 | $61,183 | 9.0% | $15.18 | +5.6% | COM | 00461U105 |
| PHVS | Pharvaris N.V. | 3,261,926 | $57,834 | 8.5% | $31.46 | -45.6% | COM | N69605108 |
| QSI | Quantum-Si Incorporated | 4,463,619 | $37,227 | 5.5% | $10.48 | -6.0% | COM CL A | 74765K105 |
| NRIX | Nurix Therapeutics, Inc. | 1,205,798 | $36,126 | 5.3% | $25.20 | +22.5% | COM | 67080M103 |
| KURA | Kura Oncology, Inc. | 1,849,947 | $34,650 | 5.1% | $20.39 | -7.6% | COM | 50127T109 |
| HLTHQ | Cue Health Inc. | 1,006,089 | $11,882 | 1.7% | $11.81 | — | COM | 229790100 |
| OLMA | Olema Pharmaceuticals, Inc. | 342,030 | $9,426 | 1.4% | $46.89 | -42.4% | COM | 68062P106 |
| — | Cymabay Therapeutics, Inc. | 1,787,094 | $6,523 | 1.0% | $3.49 | — | COM | 23257D103 |
| — | Tempest Therapeutics, Inc. | 190,213 | $2,752 | 0.4% | $11.18 | — | COM | 87978U108 |
| — | Decibel Therapeutics, Inc. | 297,711 | $2,295 | 0.3% | $11.36 | — | COM | 24343R106 |